Videos

Colleen Cotton, MD, outlines a simple screening approach that may help pediatricians identify hidradenitis suppurativa earlier.

Colleen Cotton, MD, explains how early referral, flare management, and comorbidity screening may help improve outcomes for children with hidradenitis suppurativa.

Jamie Wood, MD, explains how the FDA approval of Afrezza for children aged 6 years and older adds a new mealtime insulin option, offering flexibility beyond injections and pumps.

Early referral, school accommodations, and patient education may help improve quality of life for children with hidradenitis suppurativa.

Julie Khlevner, MD, discusses the clinical impact of FDA approval of linaclotide for children aged 2 to 5 years with functional constipation.

Colleen Cotton, MD, FAAD, outlines key skin findings that may help pediatricians distinguish hidradenitis suppurativa from other conditions.

Early diagnosis of hidradenitis suppurativa in adolescents may help prevent scarring and improve treatment response, according to Colleen Cotton, MD, FAAD.

In this episode, Dr. Simões broadens the conversation on RSV risk to include older adults and a global perspective on disease burden. He explains that while pediatric risk factors center largely on medical conditions (as described by Dr. Creech), environmental and behavioral factors — such as daycare attendance, household crowding, and maternal smoking — also play an important role in children, particularly in lower-resource settings where malnutrition adds further vulnerability.

Welcome back to another Contemporary Pediatrics Peer Exchange series. In this episode titled "RSV Epidemiology: Understanding Regional Trends and At-Risk Pediatric Populations," moderator Flor M. Munoz, MD, MSc, discusses respiratory syncytial virus with C. Buddy Creech, MD, MPH, Eric Simões, MD, and Tina Tan, MD, FAAP, FIDSA, FPIDS.

Kevin Kaiserman, MD, discusses how FDA approval of Afrezza gives children aged 6 years and older with diabetes a new mealtime insulin option.

Cedars-Sinai Guerin Children’s launched a wearable asthma monitoring program designed to help detect worsening respiratory symptoms earlier.

UCLA researchers identified EPAC2 as a potential Fragile X syndrome treatment target after improving behavioral and brain activity patterns in mice.

Most children with food allergies can maintain adequate nutrition with proper counseling, targeted food substitutions, and routine growth monitoring.

Yoshi Rothman, MD, said growing leucovorin use in autism highlights the need for larger clinical trials and careful family counseling.

Study finds leucovorin prescribing for children with autism increased more than 2,000% after national media coverage and White House promotion.

Children with anxiety, depression, and social needs had higher odds of health-related school absenteeism, according to a new study.

Rohit P. Shenoi, MD, highlighted updated AAP drowning prevention guidance focused on supervision, swim skills, and equity.

Hannah Murphy, PhD, of Vizient, discusses recent research that found children with diabetes had substantially higher rates of mental health disorders and suicide risk.

Expert recommendations outline how crinecerfont may help reduce glucocorticoid exposure in children with classic CAH.

Expert recommendations outline how crinecerfont may help reduce glucocorticoid exposure in children with classic CAH.

Third-trimester maternal COVID-19 vaccination reduced infant hospitalization risk, while prepregnancy vaccination showed no protection.

Urine F2-isoprostanes were associated with more severe viral respiratory illness in infants across 2 independent cohorts.

Existing maternal cardiac risk models showed poor prediction of neonatal complications in pregnancies complicated by congenital heart disease.

Data presented at PAS 2026 show that specific neighborhood factors—not overall scores—drive asthma outcomes, pointing to targeted interventions for reducing ED visits.

Large trial finds balanced fluids and saline yield similar outcomes in pediatric septic shock, reinforcing flexible resuscitation practices.

Natasha Wade, PhD, highlights longitudinal data showing that adolescent cannabis exposure may blunt neurocognitive development over time.

FDA expands teplizumab to children aged ≥1 year with stage 2 T1D, enabling earlier intervention to delay progression to insulin dependence.

New findings highlight elevated secondary cancer risks in adolescent and young adult survivors, underscoring the need for treatment-specific screening strategies.

Marisol Betensky, MD, outlines how dynamic risk evaluation and innovative trial designs can improve anticoagulation decision-making in pediatric VTE care.

Marisol Betensky, MD outlines how institutions can implement risk-stratified guidelines while balancing thrombosis prevention, bleeding risk, and limited evidence.